V316A (p.Val316Ala) variant of GLA (Alpha-galactosidase A)
V316A (p.Val316Ala) in GLA (Alpha-galactosidase A) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as uncertain significance in the context of Cardiovascular phenotype; Fabry disease. The available variant effect predictions contribute to a CATVariant prioritization score of 0.70 / 1. The record also includes published literature and structural context.
V316A (p.Val316Ala) variant details
- p.Val316Ala
- rs869312157
- ClinGen CA353055
- ClinVar RCV000208961
- ClinVar RCV000209520
- Uncertain significance
- Cardiovascular phenotype; Fabry disease
- Missense
- Variant Prioritization Score for Impact Estimate 0.697
- AlphaMissense 0.35
- MetaLR 0.99
- MetaSVM 1.01
- PolyPhen-2 1.00
- SIFT 0.13
- EVE 0.17
- ClinVar: Uncertain significance (Cardiovascular phenotype; Fabry disease)
- EBI: Variant of uncertain significance (in FABRYD)
- UniProt: Uncertain significance (in FABRYD)
- Structural context available
- Cited in: Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease. (PMID 26415523)
- Cited in: Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. (PMID 12735292)